StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)

Close on Nov 18, 2026Market cap $99.30MP/E –Yield –

Outlook Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Outlook Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$56.15M. For fiscal 2025 it was -$51.83M. The highest annual figure on record is -$15.51M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$51.83M–
FY2024Sep 30, 2024-$68.79M–
FY2023Sep 30, 2023-$42.97M–
FY2022Sep 30, 2022-$56.67M–
FY2021Sep 30, 2021-$54.25M–
FY2020Sep 30, 2020-$31.79M–
FY2019Sep 30, 2019-$32.29M–
FY2018Sep 30, 2018-$33.04M–
FY2017Sep 30, 2017-$15.51M–
FY2016Sep 30, 2016-$45.48M–
FY2015Sep 30, 2015-$27.48M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$21.01M–
Q2 FY2026CQ1 2026Mar 31, 2026-$7.83M–
Q1 FY2026CQ4 2025Dec 31, 2025-$14.94M–
Q4 FY2025CQ3 2025Sep 30, 2025-$12.38M–
Q3 FY2025CQ2 2025Jun 30, 2025-$11.90M–
Q2 FY2025CQ1 2025Mar 31, 2025-$16.58M–
Q1 FY2025CQ4 2024Dec 31, 2024-$10.97M–
Q4 FY2024CQ3 2024Sep 30, 2024-$16.98M–
Q3 FY2024CQ2 2024Jun 30, 2024-$19.51M–
Q2 FY2024CQ1 2024Mar 31, 2024-$19.27M–
Q1 FY2024CQ4 2023Dec 31, 2023-$13.03M–
Q4 FY2023CQ3 2023Sep 30, 2023-$12.74M–
Q3 FY2023CQ2 2023Jun 30, 2023-$13.22M–
Q2 FY2023CQ1 2023Mar 31, 2023-$8.11M–
Q1 FY2023CQ4 2022Dec 31, 2022-$8.90M–
Q4 FY2022CQ3 2022Sep 30, 2022-$10.25M–
Q1 FY2022CQ4 2021Dec 31, 2021-$10.99M–
Q4 FY2021CQ3 2021Sep 30, 2021-$8.99M–
Q1 FY2021CQ4 2020Dec 31, 2020-$13.32M–
Q4 FY2020CQ3 2020Sep 30, 2020-$12.08M–
Q3 FY2020CQ2 2020Jun 30, 2020-$5.96M–
Q2 FY2020CQ1 2020Mar 31, 2020-$7.08M–
Q1 FY2020CQ4 2019Dec 31, 2019-$6.67M–
Q4 FY2019CQ3 2019Sep 30, 2019-$5.94M–
Q3 FY2019CQ2 2019Jun 30, 2019-$10.31M–
Q2 FY2019CQ1 2019Mar 31, 2019-$6.26M–
Q1 FY2019CQ4 2018Dec 31, 2018-$9.78M–
Q4 FY2018CQ3 2018Sep 30, 2018-$8.39M-10611.9%
Q3 FY2018CQ2 2018Jun 30, 2018-$8.54M–
Q2 FY2018CQ1 2018Mar 31, 2018-$7.44M–
Q1 FY2018CQ4 2017Dec 31, 2017-$8.67M–
Q4 FY2017CQ3 2017Sep 30, 2017$79.85K–
Q3 FY2017CQ2 2017Jun 30, 2017-$5.63M–
Q2 FY2017CQ1 2017Mar 31, 2017-$4.11M–
Q1 FY2017CQ4 2016Dec 31, 2016-$5.84M–
Q4 FY2016CQ3 2016Sep 30, 2016-$10.37M–
Q3 FY2016CQ2 2016Jun 30, 2016-$16.04M–
Q2 FY2016CQ1 2016Mar 31, 2016-$7.06M–

More Outlook Therapeutics figures

See a number that looks wrong?